In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus (HBV) mutants.

The susceptibility of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir and 2,4-diamino-6-[2-(phosphonomethoxyethoxy]pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, was assessed in vitro. Most drug-resistant mutants, including multidrug resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.

Mots clés

hepatitis B virus antivirals drug resistance

Domaines

Hépatologie et Gastroentérologie

Fichier principal

PMEO_Version_3.pdf (124.84 Ko)

Fabien Zoulim : Connectez-vous pour contacter le contributeur

https://inserm.hal.science/inserm-00139473

Soumis le : lundi 2 avril 2007-15:09:35

Dernière modification le : mardi 16 avril 2024-17:00:03

Archivage à long terme le : mercredi 7 avril 2010-01:48:48

Dates et versions

inserm-00139473 , version 1 (02-04-2007)

Identifiants

HAL Id : inserm-00139473 , version 1
DOI : 10.1128/AAC.01440-06
PRODINRA : 251701
PUBMED : 17371827

Citer

Marie-Noëlle Brunelle, Julie Lucifora, Johan Neyts, Stéphanie Villet, Antony Holy, et al.. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus (HBV) mutants.. Antimicrobial Agents and Chemotherapy, 2007, 51 (6), pp.2240-3. ⟨10.1128/AAC.01440-06⟩. ⟨inserm-00139473⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM UNIV-ST-ETIENNE CNRS UNIV-LYON1 INRA UDL INRAE

217 Consultations

93 Téléchargements